Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor].

Yi chuan = Hereditas - 20 Oct 2020

Wu Yu Xian, Wang Yan

Abstract excerpt

Elevated serum level of low density lipoprotein cholesterol (LDL-C) is the leading risk factor for cardiovascular disease. LDL receptor (LDLR)-mediated LDL clearance is the major factor determining the LDL-C level in the circulation. LDL binds to the LDLR on the cell surface and enters the cells through classical clathrin-coated vesicles. In the acidic endosome, LDLR is uncoupled from LDL and recycles back to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatocytes
Share to Liposomes
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proprotein Convertase 9

Share to Receptors, LDL

Source

Identifiers

PMID: 33229322
DOI: 10.16288/j.yczz.20-065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor].PMID 33229322Read ↗

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

Molecular biology of PCSK9: its role in LDL metabolism.Semantic proximity Read ↗

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.Semantic proximity Read ↗

The PCSK9 decade.Semantic proximity Read ↗

Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.